Irbesartan/Hydrochloorthiazide Focus

Irbesartan, the active ingredient in Irbesartan/Hydrochloorthiazide Focus, is an Angiotensin II receptor blocker (ARB) presented as a combination tablet for oral use. It is used to treat hypertension, often in patients who require additional blood‑volume reduction.

GNH USA supplies Irbesartan/Hydrochloorthiazide Focus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochloorthiazide Focus is an antihypertensive medication that lowers blood pressure through dual mechanisms. - Hypertension: reduces systolic and diastolic pressure in adults with essential hypertension. - Essential hypertension: provides effective control when monotherapy is insufficient. - Hypertension with fluid retention: adds diuretic action to improve volume management.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia or severe hypokalemia - Angioedema - Liver function abnormalities - Blood dyscrasias (e.g., agranulocytosis)

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal impairment: assess kidney function and adjust therapy as needed. - Electrolyte balance: monitor serum potassium and sodium regularly. - Pregnancy: avoid use unless clearly indicated by a physician. - Concomitant drugs: review for potential interactions, especially other antihypertensives. - Elderly patients: start at lower doses and monitor for orthostatic effects. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Irbesartan/Hydrochloorthiazide Focus may interact with several medicines; careful review is required. Major Interactions (Avoid): - Dual renin‑angiotensin system blockers (e.g., ACE inhibitors, other ARBs): risk of hyperkalemia and renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels and toxicity. Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and impair renal function. - Cyclosporine or tacrolimus: heightened risk of nephrotoxicity. - Antidiabetic agents: may require dose adjustment due to blood‑glucose changes.